Alzamend Neuro (ALZN) vs Imunon (IMNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alzamend Neuro is the larger company by market cap ($6.9 million vs $6.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALZN | IMNN |
|---|---|---|
| Share price | $1.43 | $1.09 |
| Market cap | $6.90M | $6.12M |
| 1-day change | +6.72% | +1.87% |
| EPS (TTM) | $-2.30 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.68 | $5.39 |
| 52-week low | $0.84 | $1.03 |
| Distance from 52-week high | -46.64% | -79.78% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1718.18% | +1459.63% |
| Average volume | 88.67K | 155.30K |
| Shares outstanding | 4.83M | 5.61M |
| Employees | 4 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alzamend Neuro
ALZN stock →Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Imunon
IMNN stock →Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
ALZN vs IMNN FAQ
Which is bigger, Alzamend Neuro or Imunon?
Alzamend Neuro (ALZN) is larger, with a market capitalization of $6.90M compared with $6.12M for Imunon (IMNN).
Are Alzamend Neuro and Imunon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.